Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The objective of this pilot study is to evaluate the safety, tolerability and activity of the
monoclonal antibody CT-011 administered intravenously to patients with Primary Hepatocellular
Carcinoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
CureTech Ltd
Collaborators:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries